GDRX250117C10000
- 0.03
- 0.000.00%
GoodRx Newsroom
TD Cowen Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $10
Mizuho Securities Maintains GoodRx(GDRX.US) With Hold Rating
Truist Financial Maintains GoodRx(GDRX.US) With Hold Rating
GoodRx Holdings: Navigating Leadership Transition and Legislative Uncertainty
GoodRx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
GoodRx Holdings: Buy Rating Reaffirmed Amid Leadership Stability and Growth Prospects
GoodRx Holdings Is Maintained at Equal-Weight by Morgan Stanley
GoodRx Holdings Analyst Ratings
Morgan Stanley Maintains GoodRx(GDRX.US) With Hold Rating, Cuts Target Price to $6
GoodRx Report Shows Millions at Risk as Endocrinologist Shortages Hit Nearly 70% of U.S. Counties
GoodRx Stock Rises 5% After New CEO Appointment
Morgan Stanley Sticks to Their Hold Rating for GoodRx Holdings (GDRX)
Citi Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $7
Wells Fargo Maintains GoodRx(GDRX.US) With Buy Rating, Maintains Target Price $9
BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $4.5
Sell Rating Maintained for GoodRx Holdings Amid Volatility and Strategic Challenges
Positive Outlook for GoodRx Holdings Under New Leadership: Buy Rating and 52.5% Potential Return
GoodRx Names Wendy Barnes as CEO
GoodRx Appoints Healthcare Industry Veteran, Wendy Barnes, As New Chief Executive Officer >GDRX
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel